Results 71 to 80 of about 29,030 (239)

Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis – initial results from the observational SISTER study

Therapeutic Advances in Neurological Disorders
Background: The consideration of patient preference for a certain drug route of administration (RoA) plays an important role in promoting patient adherence in chronic diseases.
Ralf Gold, Stephan Schmidt, F. Deisenhammer, J. Motte, N. Richter, K. Taipale, H. C. Salmen, Christian Bohland, Ksenija Schirduan   +8 more
semanticscholar   +1 more source

Natalizumab in acute ischemic stroke (ACTION II)

Neurology, 2020
Objective We evaluated the effect of 2 doses of natalizumab on functional outcomes in patients with acute ischemic stroke (AIS). Methods In this double-blind phase 2b trial, patients with AIS aged 18–80 years with NIH Stroke Scale scores of 5–23 from 53 ...
M. Elkind, R. Veltkamp, J. Montaner, S. Johnston, A. Singhal, K. Becker, M. Lansberg, Wei-hua Tang, R. Kasliwal, J. Elkins   +9 more
semanticscholar   +1 more source

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Therapeutic Advances in Neurological Disorders, 2021
Background: Extended interval dosing of natalizumab is associated with significantly lower progressive multifocal leukoencephalopathy risk compared with every-4-week (Q4W) dosing in patients with relapsing-remitting multiple sclerosis.
H. Butzkueven, L. Kappos, T. Spelman, M. Trojano, H. Wiendl, R. Su, S. Liao, R. Hyde, S. Licata, P. Ho, N. Campbell   +10 more
semanticscholar   +1 more source

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. [PDF]

, 2018
BackgroundNo evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used
Arnold, Douglas L, Bar-Or, Amit, Belachew, Shibeshih, Bennett, Iain, Buffels, Regine, Comi, Giancarlo, Garren, Hideki, Giovannoni, Gavin, Han, Jian, Hartung, Hans-Peter, Hauser, Stephen L, Havrdová, Eva, Julian, Laura, Kappos, Ludwig, Lublin, Fred, Napieralski, Julie, Selmaj, Krzysztof, Traboulsee, Anthony   +17 more
core   +1 more source

TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal.

Multiple Sclerosis and Related Disorders, 2021
BACKGROUND A significant proportion of pediatric-onset multiple sclerosis (POMS) patients do not respond to first-line disease-modifying therapies. Clinical trials showed that natalizumab is effective and safe in adults, but there are limited clinical ...
Filipe Palavra, S. Figueiroa, A. Correia, F. Tapadinhas, J. Cerqueira, R. Guerreiro, J. de Sá, M. Sá, Sofia Almeida, Patrícia Mota, L. Sousa   +10 more
semanticscholar   +1 more source

Network Localization of Fatigue in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo, Jaakko Kungshamn, Albert Bellmunt‐Gil, Silvia Tommasin, Abhineet Ojha, Matias Viitala, Juho Aaltonen, Jyrki Lötjönen, Juha Koikkalainen, Pauli Ylikotila, Patrizia Pantano, Merja Soilu‐Hänninen, Juho Joutsa   +12 more
wiley   +1 more source

Peripheral blood biomarkers in multiple sclerosis. [PDF]

, 2015
Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. The heteroge-neity of pathophysiological processes in MS contributes to the highly variable course of the disease and unpre-dictable response to therapies ...
Acheson, Achiron, Ada Francia, Agmon-Levin, Aktas, Alatab, Alexander, Amorini, Anderson, Antonella D'Ambrosio, Arbour, Arnson, Arrambide, Ascherio, Ascherio, Ascherio, Axtell, Bar-Or, Barkhof, Barkhof, Barteneva, Bartosik-Psujek, Berger, Bertolotto, Bertolotto, Bertolotto, Bianco, Bielekova, Biomarkers Definitions Working Group, Bittner, Bloomgren, Braun, Brettschneider, Brex, Browne, Burger, Bustamante, Bustamante, Buttmann, Buzas, Bălaşa, Cantorna, Carotenuto, Carson, Cermelli, Chabas, Chen, Ciusani, Clifford, Cocucci, Colombo, Comabella, Comabella, Comabella, Comabella, Comi, Confavreux, Correale, Corvol, Cox, Creeke, D'Aurizio, D'Souza, Dalmau, De Jager, De Jager, De Santis, Deisenhammer, Derfuss, Dhib-Jalbut, Distler, Doyle, Du, Egg, Ehling, Eikelenboom, Engelhardt, Esteller, Eulalio, Fabriek, Farrell, Fenoglio, Fialová, Fissolo, Fonalledas Perelló, Fox, Freedman, Friedman, Galboiz, Gandhi, Gao, Ge, Gianchecchi, Gilli, Gilli, Giovannoni, Goldberg, Goodin, Graber, Graber, Gresle, Gresle, Guo, Haak, Haller, Hanke, Harris, Hartung, Hayes, Hecker, Hecker, Hellerqvist, Hinson, Horstman, Huang, Huang, Hur, Inoue, Ioannidis, Jimenez, Johnson, Julien, Junker, Kacperska, Kallaur, Kamath, Kasper, Kayagaki, Keller, Kemppinen, Knox, Korn, Korteweg, Kuenz, Kuhle, Kurtzke, Kvistad, Kwon, Lai, Lalive, Laroni, Lassmann, Lassmann, Lau, Lemire, Leppert, Leray, Lewis, Liang, Lily, Lin, Lindberg, Linington, Liotta, Littman, Liu, Lolli, Lopatinskaya, Lopatinskaya, Losseff, Losseff, Losy, Lovett-Racke, Lowery-Nordberg, Lublin, Lublin, Lucchinetti, Lycke, Lünemann, Lünemann, Major, Malucchi, Marchi, Markiewicz, Markovic-Plese, Martinelli-Boneschi, Marzesco, Masuoka, Mayer, Mazzali, McDonald, Miller, Minagar, Minagar, Minagar, Minagar, Missler, Mitchell, Momen-Heravi, Morel, Moreno, Mowry, Munger, Muralidharan-Chari, Murugaiyan, Myers, Nelissen, Nelissen, Norling, O'Connell, O'Connell, Oliveira, Oliver, Opdenakker, Opsahl, Otaegui, Pachner, Pachner, Pachner, Paola Margutti, Papini, Park, Pawate, Pelajo, Pender, Petereit, Peterson, Petrocca, Poloni, Probstel, Qin, Qu, Quintana, Redell, Reder, Reindl, Reindl, Rieckmann, Rieder, Riverol, Romo-Tena, Rovaris, Rudick, Rudick, Rudick, Sadiq, Salama, Sato, Schwarz, Schwarz, Selmi, Semra, Sendid, Sharief, Sharief, Sharief, Sharief, Shaw, Sheremata, Sievers, Silber, Silvia Zamboni, Siman, Simona Pontecorvo, Simpson, Soldan, Soldan, Sospedra, Srivastava, Stewart, Stüve, Sundström, Sáenz-Cuesta, Sáenz-Cuesta, Tania Colasanti, Tao, Teunissen, Tintoré, Trabattoni, Trampe, Turiák, van Horssen, Varga, Vartanian, Verderio, Villoslada, Virtanen, Vogt, Vogt, Wandinger, Wang, Waschbisch, Waubant, Waubant, Waubant, Waubant, Weinstock-Guttman, Wekerle, Xiao, Yong, Yong, Yousry, Zahednasab, Zang, Zhang, Zhu, Zipp, Zisimopoulou, Zula   +298 more
core   +1 more source

Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund, Johan Reutfors, Thomas Frisell, Fredrik Piehl   +3 more
wiley   +1 more source

Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions. [PDF]

, 2020
ObjectiveTo determine the transfer of rituximab, an anti-CD20 monoclonal antibody widely used for neurologic conditions, into mature breast milk.MethodsBreast milk samples were collected from 9 women with MS who received rituximab 500 or 1,000 mg ...
Anderson, Annika, Bevan, Carolyn, Bove, Riley, Hale, Thomas W, Krysko, Kristen M, LaHue, Sara C, Marcus, Jacqueline, Riley, Claire S, Rowles, William, Rutatangwa, Alice, Schubert, Ryan D   +10 more
core   +1 more source

CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study

Brain Pathology, 2021
Natalizumab, a recombinant humanized monoclonal antibody directed against the α4 subunit of the integrins α4ß1 and α4ß7, has been approved for the treatment of active relapsing‐remitting MS.
Darius Häusler, K. Akgün, Lidia Stork, H. Lassmann, T. Ziemssen, W. Brück, I. Metz   +6 more
semanticscholar   +1 more source